At Essenlix, we are pioneering the future of health diagnostics with our groundbreaking iMOST platform. Our team, a dynamic and multidisciplinary group of experts from industry, healthcare, and academia, excels in bio-engineering, nanotechnology, advanced imaging, artificial intelligence, machine learning, and medicine.
Essenlix was founded in 2013 by Dr. Stephen Chou and Dr. Lin Chou. Stephen Chou, is a professor at Princeton University, a member of the US National Academy of Engineering, a fellow of the US National Academy of Inventors, and a serial entrepreneur.
Essenlix’s iMOST platform represents a significant leap forward in digital health technology. Designed as an industry-first, it enables individuals to conduct self-evaluations for various diseases and health-related biomarkers—including cells, proteins, small molecules, and nucleic acids—using just a tiny drop of body fluid such as blood, saliva, urine, or sweat. Our technology delivers results within minutes, anytime and anywhere, and communicates them instantly to healthcare professionals.
The iMOST platform is not only fast, user-friendly, and cost-effective, but it also ensures the accuracy and reliability of clinical lab-quality test results. This innovative system is designed to be fault-tolerant, providing dependable outcomes even when the sample, device, process, or operation is less than perfect.
Essenlix is committed to transforming traditional, cumbersome, and costly lab testing with a convenient, mobile solution, making it the cornerstone of advanced, accessible digital health monitoring.
Newsroom
-
Essenlix Partners with Roche Diagnostics Norway to Employ Essenlix’s iMOST platform represents Sep. 10, 2024PRINCETON, N.J., May 20, 2021 /PRNewswire/ -- Essenlix Corporation, a premier developer, manufacturer, and provider of mobile instant health test solutions for personal, point-of-care, and clinical use using disruptive and proprietary advanced technology, today announced that it is partnering with Roche Diagnostics Norway to implement Essenlix's iMOSTTM platform for the Patient At-Home Test market. Related Links
-
The iMOST platform is not only fast, user-friendly, and cost-effective, but it also ensures the accuracy and reliability of clinical lab-quality test results Jun. 20, 2024Essenlix’s iMOST platform represents a significant leap forward in digital health technology. Designed as an industry-first, it enables individuals to conduct self-evaluations for various diseases and health-related biomarkers—including cells, proteins, small molecules, and nucleic acids—using just a tiny drop of body fluid such as blood, saliva, urine, or sweat. Our technology delivers results within minutes, anytime and anywhere, and communicates them instantly to healthcare professionals. The iMOST platform is not only fast, user-friendly, and cost-effective, but it also ensures the accuracy and reliability of clinical lab-quality test results. This innovative system is designed to be fault-tolerant, providing dependable outcomes even when the sample, device, process, or operation is less than perfect. Essenlix is committed to transforming traditional, cumbersome, and costly lab testing with a convenient, mobile solution, making it the cornerstone of advanced, accessible digital health monitoring.
Careers
- Coming Soon…
- Work location / ShangHai
- Recruiting Numbers / 1